Australia markets closed

Provectus Biopharmaceuticals, Inc. (PVCT)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.1930+0.0017 (+0.91%)
At close: 03:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 80.99M
Enterprise value 83.96M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)134.15
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA -29.19

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 337.41%
S&P500 52-week change 322.38%
52-week high 30.2250
52-week low 30.0560
50-day moving average 30.1820
200-day moving average 30.1248

Share statistics

Avg vol (3-month) 3325.82k
Avg vol (10-day) 3121.86k
Shares outstanding 5419.52M
Implied shares outstanding 6419.52M
Float 8385.53M
% held by insiders 19.42%
% held by institutions 10.05%
Shares short (30 Sept 2016) 41.82M
Short ratio (30 Sept 2016) 40.47
Short % of float (30 Sept 2016) 40.78%
Short % of shares outstanding (30 Sept 2016) 40.75%
Shares short (prior month 31 Aug 2016) 42.86M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:300
Last split date 311 Apr 2002

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-179.67%

Management effectiveness

Return on assets (ttm)-89.58%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)557.71k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-26.50%
Gross profit (ttm)N/A
EBITDA -2.49M
Net income avi to common (ttm)-3.1M
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)76.58k
Total cash per share (mrq)0
Total debt (mrq)3.03M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.15
Book value per share (mrq)-0.02

Cash flow statement

Operating cash flow (ttm)-2.57M
Levered free cash flow (ttm)-1.16M